Isabel Kallman grapples with perimenopause symptoms and the decision to consider hormone therapy. Experts argue that the risks associated with treatment may have been overstated, calling for a reevaluation of FDA warnings.
Doctors are pushing the FDA to remove black box warnings on low-dose estrogen treatments, arguing it discourages women from beneficial hormone therapies for menopause. Experts claim the risks are overstated and can hinder treatment.
